Immunogen (IMGN) Tops Q2 EPS by 11c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.02), $0.11 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $77.4 million versus the consensus estimate of $49.15 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Waste stocks ride AI and healthcare boom as CLH surges 27%